EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy

Jennie Lugassy, Noor Abdala-Saleh, Ghada Jarrous, Abeer Turky, Daniel Saidemberg iD, Gabriela Ridner-Bahar iD, Nir Berger iD, Dana Bar-On, Tetsuya Taura, David Wilson, Nathan Karin iD

Proceedings of the National Academy of Sciences · 22.04.2025 · 122 (16)

DOI: 10.1073/pnas.2501791122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 16.04.2025. Verfasst von Jennie Lugassy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine, Technion, Haifa 3525422, Israel. Hauptthemen laut MEDLINE: Chemokine CXCL9, Chemokine CXCL10, Dipeptidyl Peptidase 4, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DKFZ, Israel Cancer Research Fund (ICRF), Israel Science Foundation (ISF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CXCR3 is a chemokine receptor for three ligands: CXCL9, CXCL10, and CXCL11. Accumulating evidence, including data presented here, suggests that the interaction between CXCL9/CXCL10 and CXCR3 not only attracts CXCR3+ T cells but also promotes the induction of IFNγ- high effector/cytotoxic CD4+ and CD8+ T cells, establishing a CXCL9/10-CXCR3-IFNγ self-amplifying cycle that promotes efficient cancer cell killing. One of the homeostatic mechanisms that may limit this cycle is the cleavage of the two N-terminal amino acids of these chemokines by Dipeptidyl Peptidase IV (DPP-4). The modified chemokines retain their ability to bind CXCR3 but no longer activate it, becoming competitive antagonists to native CXCL9/CXCL10. To develop a DPP-4-resistant variant, we combined biochemical analysis with computational modeling, demonstrating that the addition of N-terminal glutamine (Q) to CXCL9-Fc and CXCL10-Fc rendered them fully active CXCR3 agonists, yet resistant to DPP-4 cleavage. Preclinical evaluations imply that they offer significant therapeutic potential in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL9Chemokine CXCL10Dipeptidyl Peptidase 4ImmunotherapyNeoplasmsImmunoglobulin Fc FragmentsReceptors, CXCR3HumansAnimalsMiceCell Line, TumorCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

CXCL10CXCR3DPP-4T cell subsetsimmunotherapy

Substanzen

Chemokine CXCL9Chemokine CXCL10Dipeptidyl Peptidase 4Receptors, CXCR3CXCR3 protein, humanCXCL9 protein, humanCXCL10 protein, humanImmunoglobulin Fc FragmentsDPP4 protein, human

Autor:innen und Institutionen

  • Department of Immunology, Faculty of Medicine, Technion, Haifa 3525422, Israel.
  • Research and Development, Teva Pharmaceutical Industries, Ltd., Netanya 4250419, Israel.
  • Biologics Discovery, Teva Pharmaceutical Industries Ltd., Redwood City, CA 94063.

ORCID-Profile: Daniel Saidemberg, Gabriela Ridner-Bahar, Nir Berger, Nathan Karin

Förderung

  • DKFZ
  • Israel Cancer Research Fund (ICRF)
  • Israel Science Foundation (ISF)
  • Israel Innovation authority

Zitieren

APA

Lugassy, J., Abdala-Saleh, N., Jarrous, G., Turky, A., Saidemberg, D., Ridner-Bahar, G., Berger, N., Bar-On, D., Taura, T., Wilson, D., & Karin, N. (2025). Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy. Proceedings of the National Academy of Sciences, 122(16). https://doi.org/10.1073/pnas.2501791122

Vancouver

Lugassy J, Abdala-Saleh N, Jarrous G, Turky A, Saidemberg D, Ridner-Bahar G, et al. Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy. Proceedings of the National Academy of Sciences. 2025;122(16). doi:10.1073/pnas.2501791122

BibTeX
@article{Lugassy2025,
  author = {Lugassy, Jennie and Abdala-Saleh, Noor and Jarrous, Ghada and Turky, Abeer and Saidemberg, Daniel and Ridner-Bahar, Gabriela and Berger, Nir and Bar-On, Dana and Taura, Tetsuya and Wilson, David and Karin, Nathan},
  title = {Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {16},
  doi = {10.1073/pnas.2501791122}
}
Kostenlos starten →